Brokerages Set Option Care Health, Inc. (NASDAQ:OPCH) Price Target at $32.25

Shares of Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $32.25.

Several brokerages recently commented on OPCH. JPMorgan Chase & Co. lifted their price target on shares of Option Care Health from $38.00 to $40.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. The Goldman Sachs Group lowered shares of Option Care Health from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $38.00 to $27.00 in a research note on Monday, November 4th. Truist Financial dropped their price target on shares of Option Care Health from $41.00 to $34.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Bank of America upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $26.00 to $33.00 in a research note on Monday, January 13th. Finally, JMP Securities reissued a "market outperform" rating and set a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a report on Friday, January 10th.

Institutional Trading of Option Care Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Option Care Health by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 19,315,421 shares of the company's stock valued at $448,118,000 after purchasing an additional 75,313 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Option Care Health by 84.6% in the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock valued at $425,143,000 after purchasing an additional 8,400,208 shares in the last quarter. FMR LLC lifted its holdings in shares of Option Care Health by 134.0% in the third quarter. FMR LLC now owns 7,516,448 shares of the company's stock valued at $235,265,000 after purchasing an additional 4,304,896 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Option Care Health by 10.2% in the third quarter. Westfield Capital Management Co. LP now owns 6,492,152 shares of the company's stock valued at $203,204,000 after purchasing an additional 599,589 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Option Care Health by 1.4% in the third quarter. State Street Corp now owns 6,257,172 shares of the company's stock valued at $195,849,000 after purchasing an additional 83,395 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company's stock.

Option Care Health Stock Down 1.1 %

NASDAQ:OPCH traded down $0.34 during midday trading on Wednesday, hitting $31.46. 1,115,120 shares of the company were exchanged, compared to its average volume of 1,963,724. The company has a fifty day simple moving average of $26.86 and a 200 day simple moving average of $27.94. Option Care Health has a fifty-two week low of $21.39 and a fifty-two week high of $34.63. The company has a current ratio of 1.73, a quick ratio of 1.32 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $5.35 billion, a PE ratio of 26.44, a price-to-earnings-growth ratio of 2.19 and a beta of 1.35.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.